Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. NVDA
6. PRIM
7. META
8. SPY
9. SPCX
10. DPZ

Go back to Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
Regeneron (NASDAQ: REGN) Delayed: 613.38 +0.88 (0.14%)
Previous Close $612.50    52 Week High $592.36 
Open $607.92    52 Week Low $325.35 
Day High $617.50    P/E 160.99 
Day Low $607.92    EPS $3.81 
Volume 83,036